CN1038840C - 对二氮荼衍生物、其制法及其医药用途 - Google Patents

对二氮荼衍生物、其制法及其医药用途 Download PDF

Info

Publication number
CN1038840C
CN1038840C CN92113338A CN92113338A CN1038840C CN 1038840 C CN1038840 C CN 1038840C CN 92113338 A CN92113338 A CN 92113338A CN 92113338 A CN92113338 A CN 92113338A CN 1038840 C CN1038840 C CN 1038840C
Authority
CN
China
Prior art keywords
amino
alkyl
phenopiazine
dioxo
tetrahydrochysene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92113338A
Other languages
English (en)
Chinese (zh)
Other versions
CN1072929A (zh
Inventor
A·胡斯
R·施米切尼
I·比茨
I·舒曼
L·塔斯基
P·A·洛斯克曼
D·N·斯蒂芬
D·塞德曼
M·克鲁格
D·拉兹
P·霍尔切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4135871A external-priority patent/DE4135871A1/de
Application filed by Schering AG filed Critical Schering AG
Publication of CN1072929A publication Critical patent/CN1072929A/zh
Application granted granted Critical
Publication of CN1038840C publication Critical patent/CN1038840C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN92113338A 1991-10-26 1992-10-26 对二氮荼衍生物、其制法及其医药用途 Expired - Fee Related CN1038840C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4135871A DE4135871A1 (de) 1991-10-26 1991-10-26 Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DEP4135871.6 1991-10-26
DE4224200 1992-07-17
DEP4224200.2 1992-07-17

Publications (2)

Publication Number Publication Date
CN1072929A CN1072929A (zh) 1993-06-09
CN1038840C true CN1038840C (zh) 1998-06-24

Family

ID=25908683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92113338A Expired - Fee Related CN1038840C (zh) 1991-10-26 1992-10-26 对二氮荼衍生物、其制法及其医药用途

Country Status (17)

Country Link
EP (1) EP0565683A1 (no)
JP (1) JP3258008B2 (no)
KR (1) KR100262371B1 (no)
CN (1) CN1038840C (no)
AU (1) AU664212B2 (no)
CA (1) CA2099270A1 (no)
CZ (1) CZ286351B6 (no)
FI (1) FI932959A0 (no)
HU (1) HUT64756A (no)
IL (1) IL103538A (no)
NO (1) NO304693B1 (no)
NZ (1) NZ244896A (no)
PL (1) PL171125B1 (no)
PT (1) PT101004B (no)
RU (1) RU2117663C1 (no)
SK (1) SK281518B6 (no)
WO (1) WO1993008173A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
US6096743A (en) * 1994-09-27 2000-08-01 Yamanouchi Pharmaceuticals Co., Ltd. 1,2,3,4-tetrahydroquinoxalinedione derivative
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
FR2769309B1 (fr) 1997-10-08 2001-06-15 Oreal Composition de teinture d'oxydation des fibres keratiniques comprenant un derive d'aminoacide en tant que base d'oxydation et nouveaux derives d'aminoacides
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118982A1 (en) * 1983-02-01 1984-09-19 Sumitomo Chemical Company, Limited Organic phosphorous quinoxalinone and their production and use
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse

Also Published As

Publication number Publication date
NO932344D0 (no) 1993-06-25
FI932959A (fi) 1993-06-24
NZ244896A (en) 1995-07-26
NO932344L (no) 1993-06-25
HU9301877D0 (en) 1993-09-28
PT101004A (pt) 1994-01-31
IL103538A (en) 2001-07-24
PT101004B (pt) 1999-10-29
RU2117663C1 (ru) 1998-08-20
IL103538A0 (en) 1993-03-15
PL171125B1 (pl) 1997-03-28
JP3258008B2 (ja) 2002-02-18
FI932959A0 (fi) 1993-06-24
KR100262371B1 (ko) 2000-08-01
CZ286351B6 (cs) 2000-03-15
KR930703271A (ko) 1993-11-29
AU2889492A (en) 1993-05-21
WO1993008173A1 (de) 1993-04-29
NO304693B1 (no) 1999-02-01
CZ138793A3 (en) 1994-01-19
JPH06503583A (ja) 1994-04-21
AU664212B2 (en) 1995-11-09
SK281518B6 (sk) 2001-04-09
EP0565683A1 (de) 1993-10-20
CA2099270A1 (en) 1993-04-27
HUT64756A (en) 1994-02-28
CN1072929A (zh) 1993-06-09
PL299929A1 (en) 1994-04-05
SK72793A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
CN1038840C (zh) 对二氮荼衍生物、其制法及其医药用途
CN1053190C (zh) 新的喹喔啉二酮衍生物、其制备方法和作为药物的应用
CN1309704C (zh) 邻氨基苯甲酸酰胺及其作为药物的应用
CN1174980C (zh) 抑制胃酸分泌的咪唑并吡啶衍生物
CN1031266C (zh) 含氮的六元或十元杂环的制法
CN1285578C (zh) 取代苯甲酸酰胺及其在抑制血管生成中的应用
CN1094490C (zh) 作为血清素拮抗剂的喹诺-2(1h)-酮衍生物
CN1219537A (zh) 苯并呋喃酮衍生物的制备方法
CN1688548A (zh) 喹啉抗生素中间体的制备方法
CN85104233A (zh) 化学化合物
CN1032361C (zh) 咪唑并哒嗪化合物的制备方法
CN1143956A (zh) 3,5-二取代的和3,4,5-三取代2-异噁唑啉和异噁唑,其制备方法及其作为药物的用途
CN1082964C (zh) 手性的双膦类化合物
CN1032648C (zh) 一种血小板活化因子拮抗剂的制备方法
CN1041931C (zh) [1,2,4]三唑并[4,3-a]喹喔啉化合物,它们的制备及其应用
CN1251836A (zh) 单环β-内酰胺类抗生素衍生物的中间体的制备方法
CN1061350C (zh) 2,7-取代的八氢-吡咯并[1,2-a]吡嗪衍生物
CN1918133A (zh) 用于治疗或者预防炎症性疾病的α4整联蛋白介导的细胞粘附抑制剂
CN1578662A (zh) 作为nmda-受体亚型阻断剂的吡啶衍生物
CN1051354A (zh) 取代环烷并[b]二氢吲哚-和-吲哚磺酰胺
CN1199397A (zh) 嘧啶衍生物
CN1100883C (zh) 生产l-天冬氨酸的方法
CN1025334C (zh) 新的谷氨酸衍生物的制备方法
CN1283196A (zh) N-苯基酰胺和n-吡啶基酰胺、其制备方法和含有它们的药物组合物
CN1708497A (zh) 8-取代的咪唑并吡啶类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee